Centers for Disease Control and Prevention 1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium Atlanta, Georgia 30329 February 21-22, 2018

	AGENDA ITEM	PURPOSE	PRESIDER/PRESENTER(s)
Wednesday, February 21			
8:00	Welcome & Introductions		Dr. Nancy Bennett (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
8:30	Hepatitis Vaccines		
	Introduction		Dr. Jose Romero (ACIP, WG Chair)
	Review of GRADE (HEPLISAV-B)	Information	Dr. Aaron Harris (CDC/NCHHSTP)
	Considerations and proposed recommendations	& Discussion	Dr. Sarah Schillie (CDC/NCHHSTP)
	Public comment		
	Vote	<u>Vote</u>	Dr. Sarah Schillie (CDC/NCHHSTP)
	Hepatitis A post-exposure prophylaxis GRADE	Information	Dr. Noele Nelson (CDC/NCHHSTP)
	Considerations and proposed recommendations		Dr. Noele Nelson (CDC/NCHHSTP)
	Public comment		() ()
	Vote	Vote	Dr. Noele Nelson (CDC/NCHHSTP)
10:15	Break	<u> </u>	Di Nocie Neison (eb ej Neimorr)
10:30	Influenza Vaccines		
10.50			
	Introduction		Dr. Chip Walter (ACIP, WG Chair)
	Fluarix Quadrivalent: efficacy in children 6-35 months of age		Dr. Leonard Friedland (GSK)
	Surveillance update	_	Ms. Lynnette Brammer (CDC/NCIRD)
	VE update		Dr. Brendan Flannery (CDC/NCIRD)
	Results of a randomized trial of a new H1N1 LAIV strain in US	& Discussion	Dr. Raburn Mallory (MedImmune/AstraZeneca)
	children		
	Review of LAIV for 2 through 17 year olds		Dr. Lisa Grohskopf (CDC/NCIRD), Dr. Jill
			Ferdinands (CDC/NCIRD)
	Considerations and proposed recommendations		Dr. Lisa Grohskopf (CDC/NCIRD)
	Public comment		
	Vote	<u>Vote</u>	Dr. Lisa Grohskopf (CDC/NCIRD)
	VFC Vote	VFC Vote	Dr. Jeanne Santoli
12:45	Lunch		
1:45	Evidence Based Recommendations		
	Introduction	Information	Dr. Grace Lee (ACIP, WG Chair)
	Evidence to Recommendations Framework	& Discussion	Dr. Wendy Carr (CDC/NCIRD)
	Public comment	α <i>Β</i> 130α331011	
	Vote	<u>Vote</u>	Dr. Wendy Carr (CDC/NCIRD)
2:30	Anthrax		
	Introduction		Dr. David Stephens (ACIP, WG Chair)
	Update on IM route of administration of vaccine	Information	Dr. William Bower (CDC/NCEZID)
	Dose-sparing strategies when demand for vaccine excess		Dr. William Bower (CDC/NCEZID)
	Duration of antimicrobial component of PEP when used in		Dr. William Bower (CDC/NCEZID)
	combination with anthrax vaccine		Dr. William bower (CDC/NCLZID)
3:45	Break		
4:00	Human Papillomavirus (HPV) Vaccines		
4.00	Introduction		Dr. Peter Szilagyi (ACIP, WG Chair)
	9-valent HPV vaccine safety data - VAERS update		Dr. Jorge Arana (CDC/NCEZID)
	9-valent HPV vaccine safety data - VAENS update 9-valent HPV vaccine rapid cycle analysis, Vaccine Safety		Dr. Jim Donahue (Marshfield Clinic)
		Information	
	Harmonization of upper age for male and female vaccination	& Discussion	Dr. Lauri Markowitz (CDC/NCIRD)
	recommendations Trends in HPV-associated cancers in the United States		Dr. Elizaboth Van Duno (CDC/NCCDBUD)
			Dr. Elizabeth Van Dyne, (CDC/NCCDPHP)
F.30	Epidemiology of HPV infection in males		Dr. Anil Chaturvedi (NIH/NCI)
5:30	Public Comment		

5:45 Adjourn

Thursday, February 22

Agency Updates & Unfinished Business 8:00

> CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Information

Members

9:00 Pneumococcal

> Introduction Dr. Grace Lee (ACIP, WG Chair)

PCV13 Effectiveness: Case Control Study Dr. Tamara Pilishvili (CDC/NCIRD) PCV13 Direct and Indirect Effects among Adults ≥65 Year Old Dr. Tamara Pilishvili (CDC/NCIRD)

Information Dr. John M. McLaughlin (Pfizer Vaccines) PCV13 effectiveness against pneumococcal pneumonia among

& Discussion U.S. Adults

Estimating Burden of Pneumococcal Pneumonia among Adults Dr. Almea Matanock (CDC/NCIRD) in the U.S. Progress of the research agenda to inform potential

policy change

10:30 Vaccines and other biologics for prevention and treatment of

healthcare-associated infections

Information Dr. Anthony Fiore (CDC/NCEZID) Update

11:00 **Break**

11:30 Meningococcal Disease

Introduction Dr. David Stephens (ACIP, WG Chair) Information

Epidemiology of meningococcal disease among college Dr. Sarah Meyer (CDC/NCIRD) & Discussion

students - United States, 2014-2016

12:00 Japanese Encephalitis (JE) Vaccine

Introduction Dr. Chip Walter (ACIP, WG Chair) Information Dr. Susan Hills (CDC/NCEZID)

Review of JE and work group plans & Discussion

12:15 Vaccine Supply Information Dr. Jeanne Santoli (CDC/NCIRD)

12:20 Public Comment

12:30 Adjourn

Acronyms

Centers for Disease Control & Prevention CDC Centers for Medicare and Medicaid Services **CMS**

Department of Defense DoD **Department of Veterans Affairs** DVA Food and Drug Administration FDA

Grading of Recommendations Assessment, Development and Evaluation **GRADE**

Health Resources and Services Administration HRSA

IHS Indian Health Service

JE-VC Vero cell culture-derived Japanese encephalitis

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] **NCIRD** National Center for Immunization & Respiratory Diseases [of CDC/OID] NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

National Cancer Institute NCI National Institutes of Health NIH National Vaccine Program Office **NVPO**

PCV13 13-valent pneumococcal conjugate vaccine

VFC Vaccines for Children

WG Work Group